By Sheri Kasprzak
New York, Dec. 20 - Favrille, Inc. obtained a $40 million committed equity financing facility with Kingsbridge Capital Ltd.
Under the three-year equity line, Kingsbridge may buy shares of Favrille at between 90% and 94% of the volume weighted average price of the company's stock over an eight-day pricing period.
The maximum amount Favrille may require Kingsbridge to purchase in any draw is the lesser of $10 million or 1.75% of the company's market capitalization at the time of the draw. The minimum acceptable price per share is the greater of $1.75 or 90% of the VWAP over the eight-day pricing period.
The investor will receive warrants for 250,000 shares, exercisable at $3.98 each for five years.
San Diego-based Favrille develops treatments for cancer and immune system disorders.
| Issuer: | Favrille, Inc.
|
| Issue: | Committed equity financing facility
|
| Amount: | $40 million
|
| Tenor: | Three years
|
| Price: | 90% to 94% of the VWAP over eight trading days before draw
|
| Warrants: | For 250,000 shares
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $3.98
|
| Investor: | Kingsbridge Capital Ltd.
|
| Settlement date: | Dec. 19
|
| Stock symbol: | Nasdaq: FVRL
|
| Stock price: | $2.73 at close Dec. 19
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
